Select a Region North America

Expertise

Mike Ryan

Executive Vice President, Europe

专长:

Consulting (Strategy Management & Regulatory), Stakeholder Engagement & Promotion (Patients, Payers, Providers)

With more than 25 years of experience in the life science industry, Mike has held global leadership positions in both clinical development and life-sciences software companies. Given this experience, he is highly experienced in the use of technology and understands its impact in simplifying the process of developing and delivering novel therapies and making them more accessible to patients around the world. He has worked with many biotech and pharmaceutical companies to develop clinical pathways that deliver upon the ultimate commercial goals required to ensure success for all stakeholders. Mike speaks at many global industry events to promote the idea of innovation in healthcare and to encourage a greater level of partnership between healthcare stakeholders.

Articles by Mike Ryan

New Medicines, New Access, New Frontiers

How psychedelics, cell therapies and other innovations are driving regulatory reform and new patient access Science is improving exponentially. What’s now possible, through new medicines, and entirely new categories of medicine, could only be dreamt of just a decade ago. Doctors and patients are naturally excited about the oncoming pipeline. But while science improves exponentially, […]

A Partnership Q&A with EVERSANA and Shorla Pharma

As industry and patient needs progress beyond traditional commercialization models, new models are needed to deliver products to patients quicker, especially when launching in international markets.  Still asking yourself how to execute on a global pharmaceutical product launch? EVERSANA has the answer to this question and others that you’ll have when choosing a commercialization partner.   In this Q&A, EVERSANA’s Mike Ryan, Executive Vice President, EMEA, and Sharon Cunningham, CEO […]

Why Launching in Europe Is Unlike Launching Anywhere Else

Today, there are more than half a billion people in the European Union (EU) and United Kingdom (U.K.). Passing over this part of the globe puts patients and manufacturers at risk for negative outcomes. Launching a new therapy in the EU and U.K. has traditionally involved complex navigation of service providers, price sequencing and the […]

Considering Commercial Success During Clinical Development: Maintaining a Global Perspective

Although commercial success is the ultimate goal of pharmaceutical research and development (R&D), many new treatments do not meet expectations and fail to achieve broad global reimbursement after initial regulatory approval., This causes therapies to underperform across international markets and, more importantly, limits access for patients in need. For example, only 56% of all new drugs approved by the European Medicines Agency (EMA) […]

WEBINAR: Yes EU can! How novel treatments can avoid complexity and commercialize with impact across the European continent

Europe has a population of more than 450 million people, yet most manufacturers consider the U.S. the primary market for launch. In this webinar, EVERSANA’s Mike Ryan, Executive Vice President, Europe, discusses with other industry leaders how the EU’s landscape is changing in order for European states to increasingly become a priority market for commercialization. This […]

WEBINAR: The New Path to European Pharmaceutical Commercialisation

Global healthcare and life sciences innovation continues to surge at an unprecedented rate. External disrupters such as Brexit, GDPR, new regulatory guidance, such as the Pharmaceutical Strategy for Europe, and the COVID-19 pandemic, are driving pharma and healthcare leaders to reevaluate long-standing strategies. If pharma companies want to remain globally relevant and competitive, they must reassess commercialisation strategies – particularly related to clinical […]

Change Is Happening in the EU: What Pharma Companies Need to Know About the European Union’s New Pharmaceutical Strategy

For the first time, the European Union is undergoing a major overhaul of its pharmaceutical industry with the new Pharmaceutical Strategy for Europe, which was launched in late 2020.    Through this strategy, the European Union (EU) is making changes to its infrastructure with the goal of building a holistic, patient-centered, forward-looking pharmaceutical landscape for all EU member […]

A New Pharmaceutical Strategy for Europe

In late November, the European Commission announced the adoption of a new healthcare plan – the Pharmaceutical Strategy for Europe. This plan aims to strengthen the European Health Union while ensuring affordable patient access across the entire European Union and supporting sustainable innovation for pharmaceutical industries. What’s Changing, and Why? Until now, patient access and […]

Looking To Launch Or Commercialise In The US?

Launching a product is a serious undertaking, requiring a seamless approach to building a commercialisation strategy that includes all the variables needed to maximise the investment across the product’s lifecycle. Nowhere is this more true than the world’s largest market, the United States (US). We know that a successful product launch is critical to maximising […]

Patient Recruitment & Retention: A Perspective From “The Other Side” [Webinar]

[Webinar: 23 Minutes] With over 20 years experience on the clinical research arena, Mike Ryan shares the importance of patient engagement from the clinical trial all the way across the drug development continuum. He highlights that although some patients might not qualify for the clinical trial, they should continue to be relevant as future clients/patients […]

Increase Your Speed to Market

Commercial Strategies for a Successful Product Launch. With the launch of new blockbuster drugs becoming less frequent, there is increased scrutiny on the importance and success of clinical trials, mandatory to determining the safety and efficacy of a developing product. The road to commercialization is daunting – the process of bringing a product to market […]

“Ask the Expert” About Digital Therapeutics

The promise of digital health – from wearables to mobile health apps – could revolutionize healthcare by improving adherence, reducing costs, and making treatments more personalized. Mike Ryan shares insight on the opportunity to set a commercialization standard in the digital therapeutics market that meets customer need, works with regulators and payors, and defines how […]

Ask the Expert – Digital Therapeutics

From reimbursement strategies, distribution, dispensing, patient engagement and adherence programs, EVERSANA offers integrated solutions to alleviate the barriers facing the adoption of digital therapeutics. Mike Ryan, Executive Vice President of Europe and Asia Pacific, discusses how EVERSANA is leading the commercialization of digital therapeutics with an innovative and nimble commercial model valuable to patients, providers […]

Interested in scheduling a meeting or speaking event?

联系我们

  • 这个字段是用于验证目的,应该保持不变。